Clincosm LogoSign in Get a demo

Pulmonary Hypertension Registry Switzerland

Sponsor
University of Zurich (Other)
Overall Status
Recruiting
CT.gov ID
NCT05610631
Collaborator
Actelion (Industry)
1,000
Enrollment
1
Location
126
Anticipated Duration (Months)
7.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Registry Data from PH-patients in Switzerland, who have given consent to records for research purposes.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Swiss PH Registry - Cohort of Swiss PH Patients
    Actual Study Start Date :
    Jun 1, 2017
    Anticipated Primary Completion Date :
    Dec 1, 2027
    Anticipated Study Completion Date :
    Dec 1, 2027

    Arms and Interventions

    Arm Intervention/Treatment
    Pulmonary arterial hypertension

    Pulmonary arterial hypertension
    PH due to left heart diseases

    PH due to left heart diseases
    PH due to lung disease and/or hypoxia

    PH due to lung disease and/or hypoxia
    Chronic thromboembolic PH

    Chronic thromboembolic PH
    Miscellaneous PH

    Miscellaneous PH

    Outcome Measures

    Primary Outcome Measures

    1. 6-minute walking distance [within the study duration e.g. up to 10 years]

      6-minute walking distance

    Secondary Outcome Measures

    1. New York Heart Association functional class [within the study duration e.g. up to 10 years]

      New York Heart Association functional class

    2. NTproBNP [within the study duration e.g. up to 10 years]

      NTproBNP

    3. Survival [within the study duration e.g. up to 10 years]

      time to death analysis

    4. Medication [within the study duration e.g. up to 10 years]

      escalation of clinical therapy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with PH
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Respiratory Clinic, University Hospital of Zurich Zurich Switzerland 8091

    Sponsors and Collaborators

    • University of Zurich
    • Actelion

    Investigators

    • Principal Investigator: Silvia Ulrich, Prof. Dr., UniversityHospital Zurich

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Zurich
    ClinicalTrials.gov Identifier:
    NCT05610631
    Other Study ID Numbers:
    • Swiss PH Registry
    First Posted:
    Nov 9, 2022
    Last Update Posted:
    Nov 9, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Hypertension, Pulmonary
    Hypertension

    Study Results

    No Results Posted as of Nov 9, 2022